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Background: Bone morphogenetic protein 2 (BMP-2) is a member of the TGF-β superfamily that is closely correlated
with many malignancies, particularly lung cancer. However, the effects of silenced BMP-2 on lung cancer cell
proliferation and migration are not clear.
Methods: Using quantitative real-time RT-PCR, BMP-2 mRNA expression was detected in 61 non-small cell lung
cancer (NSCLC) samples. Survival curves were generated using follow-up data. Relationships between clinical or
pathological characteristics and prognosis were analyzed. Cell viability assays and transwell migration assays were
used to evaluate the effects of BMP-2 silencing on cell proliferation and migration of A549 and H460 cells.
Results: BMP-2 mRNA expression was higher in NSCLC tissues compared to matched adjacent normal tissues (P < 0.01).
High BMP-2 expression levels were significantly associated with the occurrence of lymph node metastases and tumor
stage (P < 0.05). There were significant differences in survival curves between groups with metastatic lymph
nodes and non-metastatic lymph nodes, as well as between groups with low BMP-2 expression and groups with
high BMP-2 expression. In addition, we observed decreased proliferation and migration rates of the NSCLC-derived cell
lines A549 and H460 that were transfected with siBMP-2 (P < 0.05).
Conclusion: BMP-2 mRNA is overexpressed in NSCLC samples and is a risk factor for survival in patients with NSCLC.
BMP-2 silencing can significantly inhibit A549 and H460 cell proliferation and migration.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
4263254471298866
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Lung cancer is one of the most common causes of
cancer-related deaths, and its incidence is increasing
[1-3]. Approximately 80% of diagnosed lung cancer cases
are non-small-cell lung cancer (NSCLC) [4,5]. Despite
improvements in diagnosis and treatment, the long-term
survival rate has only marginally improved.
Bone morphogenetic protein 2 (BMP-2) was originally
identified as an osteoinductive cytokine, and was subse-
quently reported to have an important role in cell migra-
tion, proliferation, and differentiation [6,7]. Serum BMP-2* Correspondence: zhaogq@zzu.edu.cn; gjzhangzzu@126.com
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unless otherwise stated.levels from NSCLC samples were higher compared to
healthy controls, and positively correlated with poor prog-
nosis, stage, and metastatic burden [8,9]. BMP-2 protein
expression in human NSCLC is higher than in normal
lung tissue, and recombinant BMP-2 promotes cell migra-
tion and invasiveness [10]. Additionally, tumor growth
was promoted in nude mice that were injected with A549
cells that were transfected with recombinant BMP-2 [11].
Finally, BMP-2 is overexpressed in the majority of lung
carcinomas and stimulates the growth and progression of
lung tumors [12]. However, the effects of silencing BMP-2
on lung cancer cell proliferation and migration were not
clear.
In this study, we used siRNA to silence BMP-2 to ob-
serve the effect on proliferation and migration of the lung
cancer cell lines A549 and H460. Moreover, we analyzed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In this study, 61 patients with NSCLC from the First Af-
filiated Hospital of Zhengzhou University were enrolled
between 2003 and 2008. Patients who had recurrent or
primary NSCLC but received chemoradiotherapy before
surgery were excluded. Of the 61 patients, 32 were fe-
male and 29 were male. Twenty-eight cases had lymph
node metastases, whereas 33 cases did not. We obtained
paired NSCLC and adjacent non-tumor lung tissues
(located more than 5 cm away from the tumors) from
61 patients who underwent primary surgical resection
of NSCLC. All patients provided informed consent.
Both tumor and non-tumor samples were confirmed as
such by pathological examinations. These samples were
snap-frozen in liquid nitrogen after resection. The Human
Research Ethics Committee of Zhengzhou University ap-
proved this study (Table 1).
Cell lines and cell culture
The human lung cancer cell lines A549 and H460 were
maintained in DMEM supplemented with 10% fetalTable 1 Clinicopathological characteristics and BMP-2
mRNA expression in NSCLC patients (N = 61)
Parameter n Expression level P-value
Sex 0.415
Male 29 0.8383 ± 0.13541
Female 32 0.8692 ± 0.15649
Age (years) 0.312
≥60 33 0.8369 ± 0.12853
<60 28 0.8753 ± 0.16512
Differentiation
Well 19 0.8704 ± 0.15222 0.573
Moderate-poor 42 0.8473 ± 0.14509
Tumor stage 0.014*
T1 18 0.8260 ± 0.13904
T2 31 0.8290 ± 0.14797
T3–4 12 0.9632 ± 0.1066
TNM stage 0.341
I 26 0.8356 ± 0.13043
II 22 0.8458 ± 0.17847
III 13 0.9071 ± 0.11028
Nodal status 0.026*
Positive 28 0.8994 ± 0.15196
Negative 33 0.8164 ± 0.13218
*Indicates statistical significance (P < 0.05).bovine serum (FBS; Gibco), 100 units/mL penicillin, and
100 μg/mL streptomycin in a humidified incubator of
5% CO2 at 37°C.
Main materials
DMEM (coring, USA); Cell Counting Kit-8 (Dojindo
Laboratories, Japan); hematoxylin (sigma, USA); quan-
titative real time PCR assay kit(SYBR Premix Ex Taq)
(TaKaRa, Japan); Trizol (Invitrogen, USA); AMV re-
verse transcriptase (Promega, USA); the first antibody
of BMP-2, β-actin (Santa Cruz Corp, USA); the goat
anti-rabbit horseradish peroxidase-labeled secondary
antibody (Bio-Rad, USA); chemiluminescence substrate
kit (Amersham, USA); NSCLC-derived cell lines A549
and H460 were obtained from (ATCC, USA).
RNA oligo-ribonucleotides and cell transfection
siBMP-2 and negative control (NC) sequences were as
follows: siBMP-2: sense: 5′-AATAGCAGTTTCCATCACC
GA-3′; anti-sense: 3′-TTATCGTCAAAGGTAGTGGCT-
5′; negative control: sense: 5′-ATACTATTCCGAGCGAC
ATAC-3′; anti-sense: 3′-TA TGATAAGGCTCGCTGTAT
G-5′. Sequences were chemically synthesized by Shanghai
GenePharma Co., Ltd. A549 and H460 cells were seeded
into six-well plates (2 × 105 cells/well). Transfection was
performed by electroporation. Three groups were gen-
erated for the ensuing experiments: non-transfected group
(blank control), siRNA negative control-transfected group
(NC), and siBMP-2 transfected group (siRNA BMP-2). Cells
were harvested for experiments 24–48 h post-transfection.
Cell counting kit-8 assays
We used the Cell Counting Kit-8 (Dojindo Laboratories,
Japan) according to the manufacturer’s instructions to de-
termine cell viability. Briefly, cells were seeded at a density
of 2 × 103 cells/well in 96-well plates (in three replicate
wells) and treated daily for 4 consecutive days with 10 μl/
well of Cell Counting Kit-8 solution. Optical density was
measured at 450 nm to estimate the number of viable cells.
Transwell migration assays
We assayed the migration ability of cells using 6.5 mm
diameter transwell chambers with 8 μm membranes
(Corning, USA). Twenty-four hours post-transfection,
A549 and H460 cells were seeded in the upper cham-
bers, and the bottom wells were coated with 1 mg/ml
matrigel for migration assays. Media containing 10%
FBS were added to the bottom chambers. After 24 h at
37°C in a 5% CO2 humidified atmosphere, cells in the
upper chamber were carefully scraped off using a cot-
ton swab, and cells that had migrated to the basal side
of the membrane were fixed in methanol, stained with
hematoxylin, and counted. Each test was performed in
triplicate.
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We isolated total RNA from tissue samples and transfected
cells using Trizol, and cDNAs were generated using AMV
reverse transcriptase. BMP-2 primers were designed using
Oligo 7.0 software according to the BMP-2 mRNA se-
quence (NM_001200). Sequences were as follows: BMP-2
forward 5′-ATAGCAGTTTCCATCACCGAA-3′, reverse
5′-ACTTCCACCACGAAT CCAT-3′; β-actin forward 5′-
AAAGACCTGTACGCCAACACA-3′, reverse 5′-CGATC
CACACGGAGTACTTGC-3′. Primers were synthesized
by Sangon Biotech (Shanghai) Co., Ltd. Real-time RT-PCR
was performed in triplicate on the ABI 7500 Fast Real-time
PCR system. Cycling parameters were 35 denaturation
cycles of 95°C for 15 s, annealing at 55°C for 30 s, and
elongation at 72°C for 30 s. Gene expression was quan-
tified using the comparative CT method, normalizing
CT values to the housekeeping gene β-actin. After amp-
lification, melting curve analyses were performed to en-
sure the specificity of the products.
Western blotting
Total protein was extracted from transfected cells, and
protein concentrations were measured using Bradford
assays. Protein lysates (25 μg) were subjected to SDS-
PAGE. Electrophoresed proteins were transferred to nitro-
cellulose membranes (Whatman, USA). After blocking in
5% non-fat milk, membranes were washed at room
temperature and incubated with the following primary
antibodies: BMP-2 (1:1000; Santa Cruz Biotechnology,
USA) and β-actin (1:1000; Santa Cruz Biotechnology).
Following extensive washing, membranes were incu-
bated for 1 h with the goat anti-rabbit horseradish
peroxidase-labeled secondary antibody (1:3000; Bio-
Rad, USA). An enhanced chemiluminescence substrate
kit (Amersham, USA) was used to detect signals with
autoradiography film (Amersham).
Statistical analyses
Statistical analyses were performed using SPSS 17.0
software (SPSS Inc., USA). Data are expressed as the
mean ± standard deviation (SD). Student’s t-tests were
used to compare the mean between two samples. Logis-
tic analyses were used in the correlation of lymph node
metastasis with BMP-2 mRNA expression. Follow-up
data were analyzed using the Kaplan–Meier method
and log-rank tests. P-values less than 0.05 were consid-
ered statistically significant.
Results
BMP-2 mRNA is overexpressed in NSCLC samples
To explore the relationship between BMP-2 mRNA ex-
pression and NSCLC clinicopathological characteris-
tics, we retrospectively analyzed 61 NSCLC patients.
We evaluated the expression of BMP-2 mRNA usingquantitative real time RT-PCR, and explored the relation-
ship between BMP-2 mRNA levels and TNM stage, node
status, gender, age, differentiation, and tumor stage. Our
data analyses showed that the relative expression levels of
BMP-2 mRNA in cancer tissues (61 samples, 0.8545 ±
0.14650) were significantly higher compared to matched
adjacent normal tissues (61 samples, 0.1386 ± 0.0285)
(P = 0.000). In addition, there were higher BMP-2 mRNA
levels in NSCLC samples with lymph node metastasis
(28 samples, 0.8994 ± 0.15196) compared to NSCLC
samples without lymph node metastasis (33 samples,
0.8164 ± 0.13218) (P = 0.026), as well as in tumor stage
T3–4 samples (12 samples, 0.9632 ± 0.1066) compared
to tumor stage T1 samples (18 samples, 0.8260 ± 0.13904)
or T2 samples (31 samples, 0.8290 ± 0.14797) (P = 0.014)
(Table 1). These results indicate that BMP-2 expression
positively correlates with tumor stage and lymph node
metastasis in NSCLC patients.
BMP-2 mRNA expression level is a risk factor for survival
in patients with NSCLC
Survival curves were generated using the Kaplan–Meier
method. Log-rank tests indicated that there were significant
differences in survival curves from groups expressing differ-
ent BMP-2mRNA levels (χ2 = 27.108, P = 0.000, Figure 1A),
as well as between the lymph node metastatic group and
non-metastatic group (χ2 = 8.372, P = 0.004, Figure 1F).
However, there were no significant differences between
male and female patients (χ2 = 1.037, P = 0.309, Figure 1B),
patients ≥60 years versus patients <60 years old (χ2 = 0.064,
P = 0.8, Figure 1C), or patients with well differentiated
tumors versus those with moderately to poorly differenti-
ated tumors (χ2 = 0.857, P = 0.355, Figure 1D). Similarly,
there were no significant differences among the TNM
stage I, II, and III groups (χ2 = 1.317, P = 0.518, Figure 1E).
Logistic regression analysis indicated that the relative ex-
pression level of BMP-2 mRNA was a risk factor for
lymph node metastasis in patients with NSCLC.
Effects of siRNA-BMP-2 on cell proliferation
RT-PCR results showed that the mRNA expression of
BMP-2 in A549 and H460 cells transfected with siBMP-
2 was decreased compared to cells transfected with NC
and blank control (P < 0.05, Figure 2A). Further, we ex-
amined BMP-2 protein expression using western blot
analyses and found the results were consistent with the
mRNA data (P < 0.05, Figure 2B). These results demon-
strate the silencing effect of BMP-2 siRNA. According to
the CCK-8 assay results, the absorbance of A549 and
H460 cells transfected with siBMP-2 was significantly re-
duced after 2, 3, and 4 days compared with the control
cells (NC and blank) (P < 0.05, Figure 3). These results
demonstrate that silencing BMP-2 significantly inhibits
A549 and H460 cell proliferation.
Figure 1 Kaplan–Meier survival analyses. A: Schematic representation of survival curves from groups expressing different BMP-2 mRNA levels
(P = 0.000). B: Schematic representation of survival curves of different genders in patients with NSCLC (P= 0.309). C: Schematic representation of survival
curves of different ages in patients with NSCLC (P= 0.800). D: Schematic representation of survival curves of tumor differentiations in patients with
NSCLC (P = 0.355). E: Schematic representation of survival curves of different TNM stages in patients with NSCLC (P = 0.518). F: Schematic representation
of survival curves from the lymph node metastatic group and non-metastatic group in patients with NSCLC (P= 0.004).
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In order to explore the effect of BMP-2 siRNA on cell
migration, we performed transwell migration assays. We
found that the number of siBMP-2-transfected A549 or
H460 cells that traveled through the micropore mem-
brane was lower compared to the control groups (NC
and blank) (P < 0.05; Figure 4A, B). This result indicatesFigure 2 Effects of siBMP-2 on BMP-2 mRNA and protein expression i
siBMP-2 or NC. A: BMP-2 mRNA expression in cells transfected with siBMP-2 d
expression in siBMP-2-transfected cells was lower compared to control groupthat downregulation of BMP-2 inhibits the migratory
ability of A549 and H460 cells in vitro.
Discussion
Bone morphogenetic proteins (BMPs) are members of
the TGF-β superfamily and are aberrantly expressed in
many types of carcinoma cells, including prostate, lung,n A549 and H460 cells. A549 and H460 cells were transfected with
ecreased significantly compared to untransfected cells. B: BMP-2 protein
s (NC and blank).
Figure 3 Cell proliferation was assessed using CCK-8 assays. A549 and H460 cells were transfected with siBMP-2 or NC. Data are presented as
the mean of four experiments. Compared with control groups (blank and NC), BMP-2 silencing significantly decreases proliferation of the lung
carcinoma cell lines A549 (A) and H460 (B) after 2, 3, and 4 days (P < 0.05).
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stimulate proliferation, differentiation, and migration dur-
ing embryonic development [6,17-21]. BMP-2 abrogated
the fibrogenic function of TGF-β in pancreatic stellate
cells via the Smad1 signaling pathway [22]. Moreover, high
concentrations of BMP-2 strongly enhanced gastric cancer
cell motility and invasiveness [23]. BMP-2 upregulation
caused epithelial dysfunction and hyperpermeability [24],
and enhanced the neovascularization of developing lung
tumors. BMP-2 is aberrantly expressed in approximately
98% of lung carcinomas [25]. BMP-2 is highly overex-
pressed in human NCSLC compared with normal lung tis-
sue and benign lung tumors, and high BMP-2 levels
enhanced tumor cell migration and invasion, thereby
promoting tumor growth [10,11,26,27]. Thus, these
data indicate that BMP-2 has important biological ac-
tivity in lung carcinomas and a potential marker of lung
carcinomas. Up to now, several lung carcinomas poten-
tial markers had reported, such as Tiam1, MAT3, DNA
methylome [28-30].
In this study, we observed that the mRNA expression
of BMP-2 in tumor tissue was significantly higher than
in matched adjacent normal tissues (P < 0.01). Further-
more, we found that BMP-2 expression was related to
lymph node metastasis, tumor stage, and survival time.Figure 4 siBMP-2 inhibits cells migration. A549 and H460 cells were tran
migrating cells upon transfection with siBMP-2 compared to the control grThese results suggest that BMP-2 may play a role in
tumor metastasis.
High levels of BMP-2 promote tumorigenesis. However,
downregulation of BMP-2 reduced tumor growth. For ex-
ample, inhibition of BMP-2 activity using either recombin-
ant Noggin or a BMP-2 antibody caused a reduction in
lung tumor growth [10]. Blocking BMP signaling with the
inhibitor DMH1 reduced lung cell proliferation, promoted
cell death, and decreased cell migration and invasion in
NSCLC cells [31]. BMP-2 knockdown by adenovirus
inhibited growth and invasion of human lung adenocar-
cinoma cells by blocking PI3K/AKT signaling [32]. In this
study, we suppressed BMP-2 activity by siRNA. These
data show that suppressing BMP-2 expression significantly
inhibited lung tumor cell proliferation and migration
(Figures 3 and 4). This outcome is in accordance with
previous studies and further confirms the biological
function of BMP-2 in lung cancer.
Previous studies of BMP-2 have focused on the expres-
sion of BMP-2 in tumor tissues and its function in
tumor cell proliferation, invasion, and migration. How-
ever, for the first time, we investigated and assessed the
relationship between BMP-2 expression and clinicopath-
ological characteristics. Our analyses found significant
correlations between BMP-2 expression and lymph nodesfected with siBMP-2 or NC. Histograms show significantly fewer
oups (NC and blank) in A549 (A) and H460 (B) cells.
Chu et al. Diagnostic Pathology 2014, 9:123 Page 6 of 6
http://www.diagnosticpathology.org/content/9/1/123metastasis, TNM stage, tumor stage, and survival time
(Figure 1). Transwell migration assays also showed that
the number of siBMP-2-transfected cells that migrated
decreased. This result suggests that BMP-2 expression is
closely related to lung tumor metastasis.
Conclusion
In summary, our data show that BMP-2 silencing in the
lung cancer cell lines A549 and H460 suppressed their pro-
liferation and migration, thereby suggesting that BMP-2
might be a novel therapeutic strategy for human NSCLC.
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